Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Kimryn Rathmell

Showing results (1-10 of 201) with videos related to

Pageof 21
Sort By:
The Journal of Clinical Investigation|June 2, 2020
Disruptions in the realm of medical scienceW Kimryn Rathmell
Cancer Discovery|April 4, 2024
Using the National Cancer Plan to Drive Innovation in Cancer ResearchW Kimryn Rathmell
Transactions of the American Clinical and Climatological Association|September 13, 2023
LEARNING TO PIVOT: DEVELOPING TALENT AND A CHAMPIONSHIP TEAMW Kimryn Rathmell
Pharmacology & Therapeutics|January 24, 2015
Ror2 as a therapeutic target in cancerZufan Debebe, W Kimryn Rathmell
The Journal of Clinical Investigation|July 1, 2025
Vaccines in cancer treatment and prevention: the time is nowWilliam Becker, W Kimryn Rathmell
Kidney Cancer (Clifton, Va.)|October 16, 2018
Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)Pooja Ghatalia, W Kimryn Rathmell
The Journal of Clinical Investigation|November 26, 2019
The 2019 Nobel Prize honors fundamental discoveries in hypoxia responseJavid Moslehi, W Kimryn Rathmell
Expert Review of Anticancer Therapy|December 22, 2007
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatmentW Kimryn Rathmell, Shufen Chen
Current Clinical Pharmacology|April 8, 2011
Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug developmentNeal Rasmussen, W Kimryn Rathmell
Current Oncology Reports|April 29, 2010
Renal cell carcinoma: where will the state-of-the-art lead us?A Rose Brannon, W Kimryn Rathmell
Pageof 21

Showing results (1-10 of 201) with videos related to

Sort By:
Pageof 21
The Journal of Clinical Investigation|June 2, 2020
Disruptions in the realm of medical scienceW Kimryn Rathmell
Cancer Discovery|April 4, 2024
Using the National Cancer Plan to Drive Innovation in Cancer ResearchW Kimryn Rathmell
Transactions of the American Clinical and Climatological Association|September 13, 2023
LEARNING TO PIVOT: DEVELOPING TALENT AND A CHAMPIONSHIP TEAMW Kimryn Rathmell
Pharmacology & Therapeutics|January 24, 2015
Ror2 as a therapeutic target in cancerZufan Debebe, W Kimryn Rathmell
The Journal of Clinical Investigation|July 1, 2025
Vaccines in cancer treatment and prevention: the time is nowWilliam Becker, W Kimryn Rathmell
Kidney Cancer (Clifton, Va.)|October 16, 2018
Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)Pooja Ghatalia, W Kimryn Rathmell
The Journal of Clinical Investigation|November 26, 2019
The 2019 Nobel Prize honors fundamental discoveries in hypoxia responseJavid Moslehi, W Kimryn Rathmell
Expert Review of Anticancer Therapy|December 22, 2007
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatmentW Kimryn Rathmell, Shufen Chen
Current Clinical Pharmacology|April 8, 2011
Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug developmentNeal Rasmussen, W Kimryn Rathmell
Current Oncology Reports|April 29, 2010
Renal cell carcinoma: where will the state-of-the-art lead us?A Rose Brannon, W Kimryn Rathmell
Pageof 21